BACKGROUND: Ventilator-associated pneumonia (VAP) prevention is an important patient safety initiative. We describe the impact of a multidisciplinary surveillance program on VAP rates in a tertiary medical-surgical-trauma intensive care unit (ICU). METHODS: An epidemiologic surveillance program was established in 2003 as a joint project between ICU and Infection Prevention and Control Department to regularly report VAP rates to guide evidence-based VAP preventive strategies. VAP cases were diagnosed according to predefined criteria and prospectively recorded by a research physician. VAP microbiology, risk factors, and outcomes were noted. RESULTS: Of 2,812 ventilated patients, 433 (15.4%) developed VAP corresponding to 15.9 episodes per 1,000 ventilator-days. The rate decreased from 19.1 in 2003 to 6.3 per 1,000 ventilator-days in 2009. On multivariate analysis, VAP was associated with accidental extubation (hazard ratio [HR], 4.11; 95% confidence interval [CI]: 1.93-8.73), trauma versus medical diagnosis (HR, 2.59; 95% CI: 2.07-3.23), chronic obstructive pulmonary disease (HR, 1.55; 95% CI: 1.08-2.22), and neuromuscular blockade (HR, 1.39; 95% CI: 1.07-1.81). The most common isolated pathogens were Gram-negative organisms. VAP patients had longer mechanical ventilation duration, ICU and hospital length of stay, but similar ICU and hospital mortality compared with non-VAP patients. CONCLUSION: The study showed a reduction in VAP rates with active surveillance, reporting and evidence-based preventive strategies and identified several modifiable risk factors, which should be the focus of additional interventions.
BACKGROUND: Ventilator-associated pneumonia (VAP) prevention is an important patient safety initiative. We describe the impact of a multidisciplinary surveillance program on VAP rates in a tertiary medical-surgical-trauma intensive care unit (ICU). METHODS: An epidemiologic surveillance program was established in 2003 as a joint project between ICU and Infection Prevention and Control Department to regularly report VAP rates to guide evidence-based VAP preventive strategies. VAP cases were diagnosed according to predefined criteria and prospectively recorded by a research physician. VAP microbiology, risk factors, and outcomes were noted. RESULTS: Of 2,812 ventilated patients, 433 (15.4%) developed VAP corresponding to 15.9 episodes per 1,000 ventilator-days. The rate decreased from 19.1 in 2003 to 6.3 per 1,000 ventilator-days in 2009. On multivariate analysis, VAP was associated with accidental extubation (hazard ratio [HR], 4.11; 95% confidence interval [CI]: 1.93-8.73), trauma versus medical diagnosis (HR, 2.59; 95% CI: 2.07-3.23), chronic obstructive pulmonary disease (HR, 1.55; 95% CI: 1.08-2.22), and neuromuscular blockade (HR, 1.39; 95% CI: 1.07-1.81). The most common isolated pathogens were Gram-negative organisms. VAP patients had longer mechanical ventilation duration, ICU and hospital length of stay, but similar ICU and hospital mortality compared with non-VAP patients. CONCLUSION: The study showed a reduction in VAP rates with active surveillance, reporting and evidence-based preventive strategies and identified several modifiable risk factors, which should be the focus of additional interventions.
Authors: Mitchell Hamele; Chris Stockmann; Meghan Cirulis; Jay Riva-Cambrin; Ryan Metzger; Tellen D Bennett; Susan L Bratton Journal: J Neurotrauma Date: 2015-10-02 Impact factor: 5.269
Authors: D Koulenti; S Blot; J M Dulhunty; L Papazian; I Martin-Loeches; G Dimopoulos; C Brun-Buisson; M Nauwynck; C Putensen; J Sole-Violan; A Armaganidis; J Rello Journal: Eur J Clin Microbiol Infect Dis Date: 2015-09-25 Impact factor: 3.267
Authors: Hanan H Balkhy; Aiman El-Saed; Rana Maghraby; Hasan M Al-Dorzi; Raymond Khan; Asgar H Rishu; Yaseen M Arabi Journal: Ann Thorac Med Date: 2014-04 Impact factor: 2.219
Authors: Raymond M Khan; Maha Aljuaid; Hanan Aqeel; Mohammed M Aboudeif; Shaimaa Elatwey; Rajeh Shehab; Yasser Mandourah; Khalid Maghrabi; Hassan Hawa; Imran Khalid; Ismael Qushmaq; Asad Latif; Bickey Chang; Sean M Berenholtz; Sultan Tayar; Khloud Al-Harbi; Amin Yousef; Anas A Amr; Yaseen M Arabi Journal: Ann Thorac Med Date: 2017 Jan-Mar Impact factor: 2.219
Authors: Abdulhakeem O Althaqafi; Madonna J Matar; Rima Moghnieh; Adel F Alothman; Thamer H Alenazi; Fayssal Farahat; Shelby Corman; Caitlyn T Solem; Nirvana Raghubir; Cynthia Macahilig; Seema Haider; Jennifer M Stephens Journal: Infect Drug Resist Date: 2017-02-02 Impact factor: 4.003
Authors: Tjallie I I van der Kooi; Hendriek Boshuizen; Jan C Wille; Sabine C de Greeff; Jaap T van Dissel; Annelot F Schoffelen; Rolina D van Gaalen Journal: PLoS One Date: 2019-06-20 Impact factor: 3.240
Authors: Hasan M Al-Dorzi; Abdulaziz M Asiri; Abdullah Shimemri; Hani M Tamim; Sameera M Al Johani; Tarek Al Dabbagh; Yaseen M Arabi Journal: Ann Thorac Med Date: 2015 Oct-Dec Impact factor: 2.219